Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456586 | 0.85 | TSHR (0.34) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL28537993 | 0.78 | ALDH1A1 (0.35) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL1702497 | 0.73 | TSHR (0.38) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL1001811 | 0.72 | TSHR (0.36) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4637933 | 0.72 | TSHR (0.41) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL26192645 | 0.71 | ALDH1A1 (0.31) | ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8576089 | 0.71 | TSHR (0.37) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8524798 | 0.70 | TSHR (0.35) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL18329140 | 0.70 | ALDH1A1 (0.35) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL8523447 | 0.69 | TSHR (0.34) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160369017-A1 | CURABLE COMPOSITION, POLYMER FUNCTIONAL CURED PRODUCT, WATER-SOLUBLE ACRYLAMIDE COMPOUND, AND METHOD FOR MANUFACTURING SAME | FUJIFILM CORPORATION (JP) | 2016-12-22 | — | — | US | disclosed |
| US-20160369017-A1 | CURABLE COMPOSITION, POLYMER FUNCTIONAL CURED PRODUCT, WATER-SOLUBLE ACRYLAMIDE COMPOUND, AND METHOD FOR MANUFACTURING SAME | FUJIFILM CORPORATION (JP) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160369017-A1 | CURABLE COMPOSITION, POLYMER FUNCTIONAL CURED PRODUCT, WATER-SOLUBLE ACRYLAMIDE COMPOUND, AND METHOD FOR MANUFACTURING SAME | MRPL21, WDR1, CCNT1 | MEN1 804/4885KMT2A 1390/4885ALDH1A1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.